TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8007810

Group type: EXPERIMENTAL
Intervention: Entrained breathing (inspire during drive, expire during recovery; expire during drive, inspire during recovery)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Spontaneous breathing
Number of subjects: 16
Study: 2699468

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 56145

Group type: EXPERIMENTAL
Intervention: Derivates of gelatin
Number of subjects: 750

Group type: COMPARATOR
Intervention: Macrodex and Plasmasteril combined
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Haemaccel
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Gelifundol-S
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Macrodex
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Neo-Plasmagel
Number of subjects: 750
Study: 31603191

Group type: EXPERIMENTAL
Intervention: Personalized antiplatelet therapy (according to maximum aggregation rate); if MAR > 55%, 90 mg ticagrelor twice daily plus 100 mg/day aspirin; if MAR ≤ 55%, 75 mg/day clopidogrel plus 100 mg/day aspirin
Number of subjects: 2237

Group type: COMPARATOR
Intervention: Standard antiplatelet treatment (75 mg/day clopidogrel plus 100 mg/day aspirin for at least 6 months)
Number of subjects: 2237

Group type: EXPERIMENTAL
Intervention: Personalized antiplatelet therapy
Number of subjects: 2237

Group type: COMPARATOR
Intervention: Standard antiplatelet treatment
Number of subjects: 2237
Study: 31242860

Group type: EXPERIMENTAL
Intervention: Intravenous amphotericin B deoxycholate 0.7-1.0 mg/kg/day for induction therapy
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Strategies to minimize/prevent phlebitis: 1 liter of IV normal saline after each dose, rotating IV catheters every three days, infusing IV amphotericin over 4 hours, encouraging early ambulation
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Warm compresses, topical diclofenac gel, and oral anti-inflammatory medicines for severe cases
Number of subjects: 696
Study: 27989017

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1 wt% S-PRG
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 5 wt% S-PRG
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 20 wt% S-PRG
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1500 ppm fluoride as sodium monofluorophosphate (NaMFP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Toothpaste containing 0 wt% S-PRG
Number of subjects: 180
Study: 25955443

Group type: EXPERIMENTAL
Intervention: Mitii (web-based therapy programme) for 20 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 102
Study: 23731043

Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 127
Study: 22078342

Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Anaesthesia (EA)
Number of subjects: 100
Study: 19252962

Group type: EXPERIMENTAL
Intervention: 1-day mindfulness and acceptance-based workshop targeting obesity-related stigma and psychological distress
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 84
Study: 17178968

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy
Number of subjects: 0
Study: 15294364

Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg intravaginally every 4 h)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Dinoprostone (0.5 mg intracervically every 6 h)
Number of subjects: 200
Study: 11514956

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Highly Active Antiretroviral Therapy (HAART)
Number of subjects: 14
Study: 9569468

Group type: EXPERIMENTAL
Intervention: Five-component pertussis combination vaccine (CPDT‐IPV//PRP‐T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Separate injection of CPDT‐IPV and PRP‐T
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole cell pertussis combination vaccine (DPT‐IPV//PRP‐T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Component vaccines (CPDT‐IPV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole cell vaccine (DPT‐IPV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPDT‐IPV//PRP‐T
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPDT
Number of subjects: 0
Study: 7915348

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 3410154

Group type: EXPERIMENTAL
Intervention: Salbutamol administered from the Diskhaler (breath operated system)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Salbutamol administered from the metered dose inhaler
Number of subjects: 42
Study: 31235189

Group type: EXPERIMENTAL
Intervention: ChemFil Rock (zinc-reinforced glass-ionomer)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Fuji IX GP (high-viscous glass-ionomer cement)
Number of subjects: 218
Study: 28724170

Group type: EXPERIMENTAL
Intervention: Low IGF-1 levels (day 8)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Low IGFBP-3 levels (day 8)
Number of subjects: 404
Study: 27038550

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 300

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Differential Depression Treatment Response Index (DTRI)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Biological markers (DNA, RNA, plasma)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Clinical moderators
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Biological moderators and mediators
Number of subjects: 300
Study: 24714008

Group type: EXPERIMENTAL
Intervention: Crystalloid/colloid combination (750 ml crystalloid and 250 ml colloid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colloid intravenous fluid preload (500 ml)
Number of subjects: 0
Study: 21404369

Group type: EXPERIMENTAL
Intervention: Methylphenidate combined with multimodal behaviour therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Methylphenidate alone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Matched normal control group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 45
Study: 19400874

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 100 mg/day
Number of subjects: 108

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) 400 mg/day
Number of subjects: 108
Study: 17334460

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 2 mg/kg (Group K)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous propofol 3 mg/kg and intravenous fentanyl 1 microg/kg with propofol infusion of 1 mg/kg/hr (Group PF)
Number of subjects: 40
Study: 14758299

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg/dose, twice a day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 11777112

Group type: EXPERIMENTAL
Intervention: Sexual Assault Risk Reduction Program
Number of subjects: 762

Group type: COMPARATOR
Intervention: No-treatment comparison group
Number of subjects: 762
Study: 9775459

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) phenobarbital 10 micrograms/kg (n = 42 newborns)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diluted distilled water (control group, n = 46 newborns)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (not specified if in phenobarbital or control group)
Number of subjects: 100
Study: 8092438

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms/day
Number of subjects: 261

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 400 micrograms/day
Number of subjects: 261
Study: 3291140

Group type: EXPERIMENTAL
Intervention: Electronic bone growth stimulator (EBGS)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Control group (no EBGS)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Continuing nonrandomized study (I-B)
Number of subjects: 416
Study: 30902908

Group type: EXPERIMENTAL
Intervention: Guided care management led by PD nurses
Number of subjects: 328

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 328
Study: 27016000

Group type: EXPERIMENTAL
Intervention: BG00010 (50, 150, 400, 800 μg kg(‐1) in Part I; 400, 600, 1200 μg kg(‐1) in Part II)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 24652308

Group type: EXPERIMENTAL
Intervention: Flat head-of-bed (HOB) positioning
Number of subjects: 17
Study: 23794671

Group type: EXPERIMENTAL
Intervention: Group 180 (DLT rotated 180°)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Group 90 (DLT rotated 90°)
Number of subjects: 164
Study: 20839954

Group type: EXPERIMENTAL
Intervention: Mini‐PCNL
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard PCNL
Number of subjects: 69
Study: 18801405

Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/day plus ritanserin 12 mg/day (6 mg bid)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Risperidone 6 mg/day plus placebo
Number of subjects: 40
Study: 15959636

Group type: EXPERIMENTAL
Intervention: Cervical headgear treatment for at least 6 months achieving a minimum distalization of 4 mm
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Cervical headgear treatment
Number of subjects: 86
Study: 15314975

Group type: EXPERIMENTAL
Intervention: Etoposide and Cisplatin (three courses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (patients who had not undergone inductive chemotherapy)
Number of subjects: 0
Study: 10894097

Group type: EXPERIMENTAL
Intervention: Talc slurry (5 grams mixed in 150 mL of normal saline)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bleomycin (1 unit per kilogram bodyweight mixed in 150 mL of normal saline)
Number of subjects: 38
Study: 8895044

Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg capsules once daily for 3 days)
Number of subjects: 759

Group type: COMPARATOR
Intervention: Co-amoxiclav (625 mg tablet three times daily for 5-10 days)
Number of subjects: 759
Study: 8457082

Group type: EXPERIMENTAL
Intervention: Calcium-heparin (12,500 IU/day, subcutaneous)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ticlopidine (250 mg/day, oral)
Number of subjects: 40
Study: 3510602

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 242

Group type: COMPARATOR
Intervention: Chlordiazepoxide hydrochloride
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 29792485

Group type: EXPERIMENTAL
Intervention: Telephone-delivered, therapist-assisted bibliotherapy (TTB; n = 15)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Self-directed bibliotherapy (SB; n = 16)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: TTB
Number of subjects: 31

Group type: COMPARATOR
Intervention: SB
Number of subjects: 31
Study: 24470701

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia (CBT-I), 4-week group-administered program
Number of subjects: 118
Study: 22745675

Group type: EXPERIMENTAL
Intervention: Beliefs about willpower viewed as non-limited resource
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beliefs about willpower viewed as limited resource
Number of subjects: 0
Study: 19902183

Group type: EXPERIMENTAL
Intervention: 20 mg/day of rimonabant for 2 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 49
Study: 18049294

Group type: EXPERIMENTAL
Intervention: Methylphenidate 5 mg twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Methylphenidate 15 mg twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 16087278

Group type: EXPERIMENTAL
Intervention: Younger roofers
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Older roofers
Number of subjects: 37

Group type: COMPARATOR
Intervention: Older controls
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Work experience
Number of subjects: 37
Study: 12407488

Group type: EXPERIMENTAL
Intervention: OBT + T-20
Number of subjects: 547

Group type: COMPARATOR
Intervention: OBT
Number of subjects: 547
Study: 10519608

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a) discontinued before administration of gonadotropins (study group)
Number of subjects: 63

Group type: COMPARATOR
Intervention: GnRH agonist (GnRH-a) continued throughout the follicular phase (control group)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a) discontinued before administration of gonadotropins (study group) in patients with non-persistently high basal FSH
Number of subjects: 63

Group type: COMPARATOR
Intervention: GnRH agonist (GnRH-a) continued throughout the follicular phase (control group) in patients with non-persistently high basal FSH
Number of subjects: 63
Study: 7702030

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (900 mg/d for 4 mo)
Number of subjects: 30
Study: 1105627

Group type: EXPERIMENTAL
Intervention: Diazepam (10 or 20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.1 or 0.2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31234376

Group type: EXPERIMENTAL
Intervention: Gnetin-C
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 27096396

Group type: EXPERIMENTAL
Intervention: Motivational enhancement treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-management treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brief educational intervention
Number of subjects: 0
Study: 25105516

Group type: EXPERIMENTAL
Intervention: GS-9620 (0.3, 1, 2 and 4 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: GS-9620 (1, 2 and 4 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: GS-9620
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 23727829

Group type: EXPERIMENTAL
Intervention: Identical group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random group
Number of subjects: 0
Study: 21428241

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg (test formulation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rimonabant 20 mg (reference formulation)
Number of subjects: 12
Study: 19231325

Group type: EXPERIMENTAL
Intervention: Revascularization (either percutaneous coronary intervention or coronary artery bypass graft surgery)
Number of subjects: 1773

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 1773

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention
Number of subjects: 1773

Group type: COMPARATOR
Intervention: Not applicable (medical treatment)
Number of subjects: 1773
Study: 16987370

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg/kg followed by 0.05 microg/kg/min)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol (0.5 mg/kg followed by 50 microg/kg/min)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 100
Study: 14692166

Group type: EXPERIMENTAL
Intervention: Tooth-whitening gel (Colgate Simply White Night Clear Whitening Gel) used once daily at night in addition to a commercially available dentifrice.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Commercially available dentifrice only.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tooth-whitening gel (Colgate Simply White Night Clear Whitening Gel) used once daily at night.
Number of subjects: 75
Study: 10685491

Group type: EXPERIMENTAL
Intervention: CORE program (N = 54)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care (N = 56)
Number of subjects: 110
Study: 9101391

Group type: EXPERIMENTAL
Intervention: Diabetic men
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Diabetic women
Number of subjects: 236

Group type: COMPARATOR
Intervention: Non-diabetic men
Number of subjects: 236

Group type: COMPARATOR
Intervention: Non-diabetic women
Number of subjects: 236
Study: 8113493

Group type: EXPERIMENTAL
Intervention: Parent training therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Pretherapy maternal characteristics of inept discipline and antisocial behavior
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Maternal depressed mood
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Lack of negative curvature of the resistance growth curves
Number of subjects: 68
Study: 3088634

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30859218

Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 0
Study: 30169192

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 3 μg/kg
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 3 μg/kg (in boys)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo (in boys)
Number of subjects: 379
Study: 27439472

Group type: EXPERIMENTAL
Intervention: Intervention arm of the FRAGMATIC trial
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control arm of the FRAGMATIC trial
Number of subjects: 10
Study: 25506618

Group type: EXPERIMENTAL
Intervention: Motor therapy focusing on the nonparetic side along with the conventional program
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional program alone
Number of subjects: 39
Study: 21853269

Group type: EXPERIMENTAL
Intervention: L4-5 interspinous space measurements
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: L5-S1 interspinous space measurements
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation of disc height and angle with interspinous height
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation of measurements with age
Number of subjects: 100
Study: 20392347

Group type: EXPERIMENTAL
Intervention: Rifampicin (RMP) for 4 months (n = 420)
Number of subjects: 847

Group type: COMPARATOR
Intervention: Isoniazid for 9 months (n = 427)
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: RMP
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: RMP and Isoniazid
Number of subjects: 847
Study: 18514910

Group type: EXPERIMENTAL
Intervention: 12 sessions of verum acupuncture
Number of subjects: 19

Group type: COMPARATOR
Intervention: 12 sessions of sham acupuncture (control)
Number of subjects: 19
Study: 15881858

Group type: EXPERIMENTAL
Intervention: Ghee diet (10% of energy intake) for 8 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: Mustard oil diet (control) for 8 weeks
Number of subjects: 63
Study: 12778975

Group type: EXPERIMENTAL
Intervention: Locomotion condition (children exploring the maze by walking)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Non-locomotion condition (children surveying the maze)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Locomotion condition (children exploring the maze)
Number of subjects: 144
Study: 10223020

Group type: EXPERIMENTAL
Intervention: Expert oriented (EXP) bulletin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spiritual and pastor-oriented (SPIR) bulletin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8709183

Group type: EXPERIMENTAL
Intervention: Aspirin and IVGG 400 mg/kg/day for 5 consecutive days
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Aspirin and single high dose IVGG (2 gm/kg) for 10-12 hours
Number of subjects: 293

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 293
Study: 1882923

Group type: EXPERIMENTAL
Intervention: 0.25% levobunolol
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.25% timolol
Number of subjects: 80
Study: 7090992

Group type: EXPERIMENTAL
Intervention: Atrial stimulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ventricular stimulation
Number of subjects: 10
Study: 31014147

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine treatment group (n=25)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (normal saline, n=24)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 29785101

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 µg once-daily maintenance therapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard care for AECOPD and RTI
Number of subjects: 140
Study: 27821982

Group type: EXPERIMENTAL
Intervention: Mifepristone with Vaginal Misoprostol (Group-A)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (Group-B)
Number of subjects: 280
Study: 24700398

Group type: EXPERIMENTAL
Intervention: CC/Gn/GnRH‐ant 'mild' protocol
Number of subjects: 695

Group type: COMPARATOR
Intervention: GnRH‐agonist and high‐dose Gn 'long' protocol
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 695
Study: 23081661

Group type: EXPERIMENTAL
Intervention: Image-guided surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 20
Study: 19399499

Group type: EXPERIMENTAL
Intervention: Mobile bearing type
Number of subjects: 68

Group type: COMPARATOR
Intervention: Fixed bearing type
Number of subjects: 68
Study: 17459013

Group type: EXPERIMENTAL
Intervention: Self-reported willingness-to-pay (WTP) for a theoretical treatment with a cure rate of 85%
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Self-reported annual income
Number of subjects: 46
Study: 15226331

Group type: EXPERIMENTAL
Intervention: Topotecan (1.5 mg/m² on days 1 through 5, four cycles, every 3 weeks)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Topotecan
Number of subjects: 273
Study: 11343045

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg added to budesonide 200 microg twice daily
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo added to budesonide 200 microg twice daily
Number of subjects: 279
Study: 9633737

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 10 mg every 12 hours, increased weekly up to a maximum of 30 mg every 12 hours
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 50
Study: 7869315

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SPECT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MRI and SPECT combined
Number of subjects: 24